Evan Mizerak, on Developing an ASO Targeting CAPN2 for ALS ByEvan MizerakMarch 7th 2024The lead of preclinical research at Amylyx Pharmaceuticals discussed the literature supporting AMX0114’s target and its upcoming trial design.